Jorge Nieva, MD - Keck School of ...

Dr. Jorge J. Nieva

Claim this profile

USC / Norris Comprehensive Cancer Center

Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
18 reported clinical trials
27 drugs studied

About Jorge J. Nieva

Education:

  • Earned an MD (Doctor of Medicine) from an unspecified institution.

Experience:

  • Associated with the USC Norris Comprehensive Cancer Center, a part of the Keck School of Medicine at USC.
  • Serves as a medical oncologist, specializing in cancer treatment and research.
  • Engages in a multidisciplinary team approach to enhance patient care, prevention, research, and education in cancer treatment.

Area of expertise

1

Lung Cancer

Jorge J. Nieva has run 10 trials for Lung Cancer. Some of their research focus areas include:

Stage III
Stage II
Stage IV
2

Non-Small Cell Lung Cancer

Jorge J. Nieva has run 8 trials for Non-Small Cell Lung Cancer. Some of their research focus areas include:

Stage III
Stage IV
Stage II

Affiliated Hospitals

Image of trial facility.

USC / Norris Comprehensive Cancer Center

Image of trial facility.

Los Angeles County-USC Medical Center

Clinical Trials Jorge J. Nieva is currently running

Image of trial facility.

Tazemetostat + Topotecan + Pembrolizumab

for Small Cell Lung Cancer

This phase I trial tests the safety, side effects, and best dose of tazemetostat in combination with topotecan and pembrolizumab in treating patients with small cell lung cancer that has come back after a period of improvement (recurrent). Tazemetostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as topotecan, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving tazemetostat in combination with topotecan and pembrolizumab may shrink or stabilize recurrent small cell lung cancer.

Recruiting

1 award

Phase 1

19 criteria

Image of trial facility.

Pembrolizumab

for Leukoplakia

This trial studies how well pembrolizumab works in treating leukoplakia. Pembrolizumab helps the immune system fight cancer by blocking a protein that prevents immune cells from attacking cancer cells. The trial targets patients with leukoplakia, aiming to see if this medication can effectively treat this condition. Pembrolizumab is an immune checkpoint inhibitor that has been used in the treatment of various cancers, including non-small cell lung cancer, melanoma, and head and neck cancers.

Recruiting

1 award

Phase 2

More about Jorge J. Nieva

Clinical Trial Related

6 years of experience running clinical trials · Led 18 trials as a Principal Investigator · 2 Active Clinical Trials

Treatments Jorge J. Nieva has experience with

  • Pembrolizumab
  • Carboplatin
  • Pemetrexed
  • Nivolumab
  • Biospecimen Collection
  • Berzosertib

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Jorge J. Nieva specialize in?

Is Jorge J. Nieva currently recruiting for clinical trials?

Are there any treatments that Jorge J. Nieva has studied deeply?

What is the best way to schedule an appointment with Jorge J. Nieva?

What is the office address of Jorge J. Nieva?

Is there any support for travel costs?